YTEN Share Price | Yield10 Bioscience, Inc. Stock Analysis & Recommendation

Q: How big is Yield10 Bioscience, Inc.?

Market Cap: As of Jun 13, Yield10 Bioscience, Inc. has a market capitalization of 0.01, which classifies it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Yield10 Bioscience, Inc. reported net sales of 0.75 million and a net profit of -12.71 million.Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of -2.48 million and total assets of 3.91 million.

Q: Is Yield10 Bioscience, Inc. overvalued or undervalued?

As of 8 March 2018, Yield10 Bioscience, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is considered overvalued given its negative financial ratios, including a P/E ratio of -0.0008 and an EV to EBITDA of -0.08, both of which reflect a lack of profitability and operational efficiency. The current price of $0.01 is a stark contrast to its 52-week high of $2.33, highlighting the substantial decline in market perception.In comparison to peers, Yield10 Bioscience's valuation metrics are notably poor. For instance, CVR Partners LP is rated very attractive with a P/E of 12.50, while Oil-Dri Corp. of America shows a strong P/E of 22.31. This stark contrast underscores the challenges Yield10 faces in attracting investor interest. Additionally, the company's year-to-date return of -95.19% compared to the S&P 500's 2.44% reinforces the notion that it is significantly overvalued in the current market environment.

Q: Is Yield10 Bioscience, Inc. technically bullish or bearish?

As of 11 February 2025, the technical trend for Yield10 Bioscience, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages remain bearish, and the Bollinger Bands show a sideways trend on the weekly and mildly bearish on the monthly.The KST indicates a mildly bullish stance on the weekly but is bearish on the monthly, and both the Dow Theory and OBV show no trend in either time frame. Yield10 has experienced significant declines, with a year-to-date return of -99.97% compared to a 12.22% gain in the S&P 500, highlighting a stark underperformance. Overall, the current technical stance is mildly bearish with mixed signals across different indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

166

Shareholding (Jun 2024)

FII

0.11%

Held by 3 FIIs

DII

98.8%

Held by 1 DIIs

Promoter

0.00%

How big is Yield10 Bioscience, Inc.?

22-Jun-2025

As of Jun 13, Yield10 Bioscience, Inc. has a market capitalization of 0.01, classifying it as a Micro Cap company, with net sales of 0.75 million and a net profit of -12.71 million over the last four quarters. As of Dec 23, the company reported shareholder's funds of -2.48 million and total assets of 3.91 million.

View full answer

Who are in the management team of Yield10 Bioscience, Inc.?

22-Jun-2025

As of March 2022, the management team of Yield10 Bioscience, Inc. includes Chairman Robert Van Nostrand, CEO Dr. Oliver Peoples, and Directors Dr. Sherri Brown, Dr. Richard Hamilton, Mr. Joseph Shaulson, and Dr. Anthony Sinskey. They are responsible for the company's strategic direction.

View full answer

Is Yield10 Bioscience, Inc. overvalued or undervalued?

25-Jun-2025

Yield10 Bioscience, Inc. is considered overvalued with a negative P/E ratio and EV to EBITDA, reflecting poor financial performance, and its current price of $0.01 is significantly lower than its 52-week high of $2.33, especially when compared to more attractive peers like CVR Partners LP and Oil-Dri Corp. of America.

View full answer

Is Yield10 Bioscience, Inc. technically bullish or bearish?

20-Sep-2025

As of February 11, 2025, Yield10 Bioscience, Inc. shows a mildly bearish trend with mixed signals across indicators, including mildly bullish MACD readings, bearish daily moving averages, and a significant year-to-date decline of 99.97%.

View full answer

Compare Yield10 Bioscience, Inc. with Similar Stocks

Snow Lake Resources Ltd.China Green Agriculture, Inc.Oil-Dri Corp. of America

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Chemicals & Petrochemicals

Market cap

USD 0 Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.15

Return on Equity

203.62%

Price to Book

0.00

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2024)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

-100.0%

1 Year

-100.0%

2 Years

-100.0%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Yield10 Bioscience, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

1.92%

EBIT Growth (5y)

-12.36%

EBIT to Interest (avg)

-10.93

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.15

Sales to Capital Employed (avg)

0.02

Tax Ratio

1.02%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.51%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

-0.07

EV to EBITDA

-0.08

EV to Capital Employed

-0.18

EV to Sales

0.94

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

203.62%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (1.09%)

Foreign Institutions

Held by 3 Foreign Institutions (0.11%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 13.51% vs -8.82% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.10",
          "val2": "-3.60",
          "chgp": "13.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-3.70",
          "chgp": "13.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7,117.80%",
          "val2": "0.00%",
          "chgp": "-711.78%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -75.00% vs -33.33% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -6.62% vs -23.64% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.10",
          "val2": "-12.80",
          "chgp": "-10.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.50",
          "val2": "-13.60",
          "chgp": "-6.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-240,283.30%",
          "val2": "-29,891.10%",
          "chgp": "-21,039.22%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY

Jun'24

Jun'23

Change(%)

Net Sales

0.40

0.00

Operating Profit (PBDIT) excl Other Income

-3.10

-3.60

13.89%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-3.20

-3.70

13.51%

Operating Profit Margin (Excl OI)

-7,117.80%

0.00%

-711.78%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023

Consolidated Net Profit

YoY Growth in quarter ended Jun 2024 is 13.51% vs -8.82% in Jun 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

0.10

0.40

-75.00%

Operating Profit (PBDIT) excl Other Income

-14.10

-12.80

-10.16%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.50

-13.60

-6.62%

Operating Profit Margin (Excl OI)

-240,283.30%

-29,891.10%

-21,039.22%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is -75.00% vs -33.33% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -6.62% vs -23.64% in Dec 2022

All Annual Results

Company CV

About Yield10 Bioscience, Inc.

Yield10 Bioscience, Inc.

Chemicals & Petrochemicals

Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.

Company Coordinates

Company Details

19 Presidential Way Ste 201 , WOBURN MA : 01801-1184

Tel: 1 617 5831700

http://www.yield10bio.com/

Registrar Details